Glyco-modified atrial natriuretic peptide
AssigneeDaiichi Sankyo Company, Limited
InventorsMitsuhiro Iwamoto, Takahiro Yamaguchi, Yutaka Mori, Keiji Saito, Takeshi Honda, Takahiro Nagayama
Life of this patent
Estimating the term…
Abstract
The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.
Claims12
A modified peptide or a pharmaceutically acceptable salt thereof, wherein the modified peptide has a structure of
- wherein hANP is hANP(1-28) consisting of the amino acid sequence of SEQ ID NO:
- 1 and is bonded at the N terminus of the amino acid sequence to the linker structure through an amide bond;
- and
- SG is a sugar substance of following formula
- wherein Gxx is GlcNAc and “O/N-L” represents binding to the linker structure through an O-glycosidic bond.
Dependencies are inferred from the claim text.